alexa Pyrazolylamine Derivatives Reveal The Conformational Switching Between Type I And Type II Binding Modes Of Anaplastic Lymphoma Kinase (ALK)
ISSN: 0974-276X

Journal of Proteomics & Bioinformatics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

8th International Conference on Proteomics and Bioinformatics
May 22- 24, 2017 Osaka, Japan

Su-Ying Wu
National Health Research Institutes, Taiwan
Posters & Accepted Abstracts: J Proteomics Bioinform
DOI: 10.4172/0974-276X-C1-098
Abstract
Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type-I binding mode, but only limited type-II ALK structural studies are available. Herein, we present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl) amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type- II binding mode. It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK. A structure-activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK. To the best of our knowledge, this is the first structural biology study to directly observe how changes in the structure of a small molecule can regulate the switch between the type I and type II binding modes, and induce dramatic conformational changes.
Biography

Su-Ying Wu has her expertise in protein chemistry, protein crystallography and structure-based drug design. Her studies were Ph.D., Structural Biochemistry, University of Edinburgh, Edinburgh, UK (1995) and B.S., Chemistry, National Taiwan University, Taipei, Taiwan (1990).

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords